Zhe Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Zhe Wang has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Guoliang Li
Tsinghua University
2 shared publications - Qiangwei Zhou
National Key Laboratory of Crop Genetic Improvement, Hubei Hongshan Laboratory, Huazhong Agricultural University, Wuhan 430070, China
2 shared publications - Xiong-Hui Zhou
College of Informatics, Huazhong Agricultural University, Wuhan, People’s Republic of China
2 shared publications - Yuanhui Sun
Huazhong Agricultural University National Key Laboratory of Crop Genetic Improvement, Hubei Hongshan Laboratory Wuhan 430070
2 shared publications - Yuying Hou
Huazhong Agricultural University National Key Laboratory of Crop Genetic Improvement, Hubei Hongshan Laboratory Wuhan 430070
2 shared publications - Zhixian Zhu
Huazhong Agricultural University National Key Laboratory of Crop Genetic Improvement, Hubei Hongshan Laboratory Wuhan 430070
2 shared publications
Latest Publications
- Open Access
- 14 October 2025
- Published by Oxford University Press (OUP) in Genomics, Proteomics & Bioinformatics
- Vol. 24 (2)
cfMethDB: A Comprehensive cfDNA Methylation Data Resource for Cancer Biomarkers
Cancer is a major global health threat, and early detection is crucial for improving patient outcomes. DNA methylation in circulating cell-free DNA (cfDNA) has emerged as a promising biomarker for non-invasive cancer diagnosis. However, the integration and utilization of existing cfDNA methylation data have been limited, hindering comprehensive research efforts, particularly in the discovery of cfDNA methylation biomarkers. To address this challenge, we introduce cfMethDB, a comprehensive database dedicated to cfDNA methylation in cancer that encompasses 4828 publicly available datasets. Through standardized analysis, we identified 1,048,770 differentially methylated cytosines (DMCs) as candidate biomarkers across seven cancer types. With cfMethDB, we not only identified known cfDNA methylation biomarkers, but also discovered several genes, such as ZIC4, that could be novel biomarkers. Moreover, cfMethDB offers a suite of user-friendly tools, including biomarker evaluation, pan-cancer search, and end motif analysis. We hope that cfMethDB will serve as a valuable platform for the discovery of novel cancer cfDNA methylation biomarkers and will facilitate cancer research and clinical applications. cfMethDB is publicly available at: https://cfmethdb.hzau.edu.cn/home.
- 14 October 2025
- Published by Oxford University Press (OUP) in Genomics, Proteomics & Bioinformatics
- Vol. 24 (2)
Open AccesscfMethDB: A Comprehensive cfDNA Methylation Data Resource for Cancer Biomarkers
Cancer is a major global health threat, and early detection is crucial for improving patient outcomes. DNA methylation in circulating cell-free DNA (cfDNA) has emerged as a promising biomarker for non-invasive cancer diagnosis. However, the integration and utilization of existing cfDNA methylation data have been limited, hindering comprehensive research efforts, particularly in the discovery of cfDNA methylation biomarkers. To address this challenge, we introduce cfMethDB, a comprehensive database dedicated to cfDNA methylation in cancer that encompasses 4828 publicly available datasets. Through standardized analysis, we identified 1,048,770 differentially methylated cytosines (DMCs) as candidate biomarkers across seven cancer types. With cfMethDB, we not only identified known cfDNA methylation biomarkers, but also discovered several genes, such as ZIC4, that could be novel biomarkers. Moreover, cfMethDB offers a suite of user-friendly tools, including biomarker evaluation, pan-cancer search, and end motif analysis. We hope that cfMethDB will serve as a valuable platform for the discovery of novel cancer cfDNA methylation biomarkers and will facilitate cancer research and clinical applications. cfMethDB is publicly available at: https://cfmethdb.hzau.edu.cn/home.
- Open Access
cfMethDB: a comprehensive cfDNA methylation data resource for cancer biomarkers
Cancer is a major global health threat, and early detection of cancer is crucial for improving patient outcomes. DNA methylation in circulating cell-free DNA (cfDNA) has emerged as a promising biomarker for non-invasive cancer diagnosis. However, the integration and utilization of existing cfDNA methylation data have been limited, hindering comprehensive research efforts, especially in the discovery of cfDNA methylation biomarkers. To address this challenge, we introduce cfMethDB, a comprehensive database dedicated to cfDNA methylation in cancer that encompasses 4828 publicly available datasets. Through standardized analysis, we identified 1,048,770 differentially methylated cytosines (DMCs) as candidate biomarkers across seven cancer types. With cfMethDB, we not only identified known cfDNA methylation biomarkers, but also discovered several genes, such as ZIC4 , that could be novel biomarkers. Moreover, cfMethDB offers a suite of user-friendly tools, including biomarker evaluation, pan-cancer search and end motif analysis. We hope that cfMethDB will serve as a valuable platform for the discovery of novel cancer cfDNA methylation biomarkers and will facilitate cancer research and clinical applications. cfMethDB is publicly available at: https://cfmethdb.hzau.edu.cn/home .
Open AccesscfMethDB: a comprehensive cfDNA methylation data resource for cancer biomarkers
Cancer is a major global health threat, and early detection of cancer is crucial for improving patient outcomes. DNA methylation in circulating cell-free DNA (cfDNA) has emerged as a promising biomarker for non-invasive cancer diagnosis. However, the integration and utilization of existing cfDNA methylation data have been limited, hindering comprehensive research efforts, especially in the discovery of cfDNA methylation biomarkers. To address this challenge, we introduce cfMethDB, a comprehensive database dedicated to cfDNA methylation in cancer that encompasses 4828 publicly available datasets. Through standardized analysis, we identified 1,048,770 differentially methylated cytosines (DMCs) as candidate biomarkers across seven cancer types. With cfMethDB, we not only identified known cfDNA methylation biomarkers, but also discovered several genes, such as ZIC4 , that could be novel biomarkers. Moreover, cfMethDB offers a suite of user-friendly tools, including biomarker evaluation, pan-cancer search and end motif analysis. We hope that cfMethDB will serve as a valuable platform for the discovery of novel cancer cfDNA methylation biomarkers and will facilitate cancer research and clinical applications. cfMethDB is publicly available at: https://cfmethdb.hzau.edu.cn/home .
- 1 July 2020
- Published by Elsevier in Neurobiology of Aging
- Vol. 91, 167.e11-167.e19
Impact of modifiable risk factors on Alzheimer's disease: A two-sample Mendelian randomization study
- 1 July 2020
- Published by Elsevier in Neurobiology of Aging
- Vol. 91, 167.e11-167.e19
Impact of modifiable risk factors on Alzheimer's disease: A two-sample Mendelian randomization study